drugset / Trial / NCT05177770
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 2
Terminated
16 enrolled
Coherus Oncology, Inc.
Arcus Biosciences, Inc. · collabSurface Oncology · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2022-01-17
- Primary completion
- 2023-04-05
- Completion
- 2023-04-05
Outcome
Outcome not reported
Stopped (Business): “The study was terminated for strategic reasons, not due to any safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etrumadenant | Small molecule | — | — |
| Subject | PERENOSTOBART | Monoclonal antibody | — | — |
| Subject | Zimberelimab | Monoclonal antibody | — | — |